These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 25079580)

  • 1. Valproate-induced pseudoatrophy: expanding the clinical and imaging spectrum.
    Lovett M; Skidmore DL; Mohamed IS
    Pediatr Neurol; 2014 Aug; 51(2):284-5. PubMed ID: 25079580
    [No Abstract]   [Full Text] [Related]  

  • 2. Brain pseudoatrophy and mental regression on valproate and a mitochondrial DNA mutation.
    Galimberti CA; Diegoli M; Sartori I; Uggetti C; Brega A; Tartara A; Arbustini E
    Neurology; 2006 Nov; 67(9):1715-7. PubMed ID: 17101920
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversible cortical atrophy and cognitive decline induced by valproic acid.
    Straussberg R; Kivity S; Weitz R; Harel L; Gadoth N
    Eur J Paediatr Neurol; 1998; 2(4):213-8. PubMed ID: 10726594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible cognitive and neurological symptoms during valproic acid therapy.
    Hommet C; Mondon K; de Toffol B; Constans T
    J Am Geriatr Soc; 2007 Apr; 55(4):628. PubMed ID: 17397449
    [No Abstract]   [Full Text] [Related]  

  • 5. Pseudoatrophy of the brain with valproic acid monotherapy.
    McLachlan RS
    Can J Neurol Sci; 1987 Aug; 14(3):294-6. PubMed ID: 3117347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment.
    Guerrini R; Belmonte A; Canapicchi R; Casalini C; Perucca E
    Epilepsia; 1998 Jan; 39(1):27-32. PubMed ID: 9578009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epilepsy: Should valproate be avoided during childbearing years?
    Maccotta L; Sullivan JE
    Nat Rev Neurol; 2009 Aug; 5(8):414-5. PubMed ID: 19657344
    [No Abstract]   [Full Text] [Related]  

  • 8. Valproate-induced hyperammonemia as a cause of altered mental status.
    Feil D; Chuang K; Sultzer DL
    Am J Geriatr Psychiatry; 2002; 10(4):476-8. PubMed ID: 12095907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversible dementia and gait disturbance after prolonged use of valproic acid.
    Evans MD; Shinar R; Yaari R
    Seizure; 2011 Jul; 20(6):509-11. PubMed ID: 21435910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproate-induced reversible pseudoatrophy of the brain and hyperammonemic encephalopathy in a bipolar patient.
    Abreu LN; Issler C; Lafer B
    Aust N Z J Psychiatry; 2009 May; 43(5):484-5. PubMed ID: 19382315
    [No Abstract]   [Full Text] [Related]  

  • 11. [Reversible Parkinsonism and cognitive impairment following treatment with valproate].
    Toribio-Díaz ME; Morera-Guitart J; Palao-Duarte S
    Rev Neurol; 2008 Oct 1-15; 47(7):390-1. PubMed ID: 18841554
    [No Abstract]   [Full Text] [Related]  

  • 12. Valproate-induced hyperammonemia and seizures: perioperative concerns.
    Garg R; Sunder RA
    Paediatr Anaesth; 2011 Oct; 21(10):1084-5. PubMed ID: 21981101
    [No Abstract]   [Full Text] [Related]  

  • 13. Valproate-induced reversible hemichorea.
    Srinivasan S; Lok AW
    Mov Disord; 2010 Jul; 25(10):1511-2. PubMed ID: 20629154
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cognitive impairment caused by valproate].
    Villosladaa P; Borrás C; Montalbán X
    Med Clin (Barc); 2000 Dec; 115(20):799. PubMed ID: 11171459
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cognitive effects of antiepileptic drugs].
    Trimble R
    Rev Neurol (Paris); 1987; 143(5):420-8. PubMed ID: 3116640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare magnetic resonance imaging findings in medium-chain acyl-coenzyme A dehydrogenase deficiency.
    Das S; Joardar S; Chatterjee R; Guha G; Hashmi MA
    Pediatr Neurol; 2011 Sep; 45(3):203-5. PubMed ID: 21824573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproate-induced worsening of seizures: clue to underlying diagnosis.
    Dhamija R; Gavrilova RH; Wirrell EC
    J Child Neurol; 2011 Oct; 26(10):1319-21. PubMed ID: 21454832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproate induced isolated neutropenia.
    Kohli U; Gulati S
    Indian J Pediatr; 2006 Sep; 73(9):844. PubMed ID: 17006050
    [No Abstract]   [Full Text] [Related]  

  • 19. Factor VII deficiency associated with valproate treatment.
    Unalp A; Dirik E; Kurul S
    Pediatr Int; 2008 Jun; 50(3):403-5. PubMed ID: 18533961
    [No Abstract]   [Full Text] [Related]  

  • 20. Generalized onycholysis associated with sodium valproate therapy.
    Grech V; Vella C
    Eur Neurol; 1999 Jul; 42(1):64-5. PubMed ID: 10523137
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.